News
SILO
6.05
+4.95%
0.29
Psychedelic: Definium soars on study results for LSD-based depression treatment
TipRanks · 2d ago
Silo Pharma reports positive stability data for stress treatment SPC-15
TipRanks · 4d ago
Silo Pharma Confirms Nine‑Month Stability Of SPC‑15 Intranasal Prophylactic, Supporting IND‑Enabling CMC Documentation.
Benzinga · 4d ago
Silo Pharma reports SPC-15 PTSD nasal spray shows nine-month stability, supports Phase 1 trial plan
PUBT · 4d ago
SILO PHARMA REPORTS POSITIVE STABILITY DATA FOR SPC-15 PTSD TREATMENT, ADVANCING PROGRAM TOWARD FIRST-IN-HUMAN CLINICAL TRIAL
Reuters · 4d ago
Weekly Report: what happened at SILO last week (0615-0619)?
Weekly Report · 5d ago
Silo Pharma Regains Nasdaq Compliance, Stabilizing Listing Status
TipRanks · 06/19 00:38
Silo Pharma announces annual shareholder meeting
PUBT · 06/18 21:13
*Silo Pharma Regains Compliance With Nasdaq Minimum Bid Price Requirement
Dow Jones · 06/18 12:12
Weekly Report: what happened at SILO last week (0608-0612)?
Weekly Report · 06/15 09:44
Weekly Report: what happened at SILO last week (0601-0605)?
Weekly Report · 06/08 09:41
Silo Pharma Implements Reverse Stock Split and Restructures Capital
TipRanks · 06/03 22:46
Silo Pharma Inc trading halted, news pending
TipRanks · 06/02 23:50
Silo Pharma Announces 1-for-15 Reverse Stock Split
TipRanks · 06/01 13:58
Silo Pharma executes 1-for-15 reverse stock split effective June 2
PUBT · 06/01 13:04
Weekly Report: what happened at SILO last week (0525-0529)?
Weekly Report · 06/01 09:44
Weekly Report: what happened at SILO last week (0518-0522)?
Weekly Report · 05/25 09:45
Weekly Report: what happened at SILO last week (0511-0515)?
Weekly Report · 05/18 09:45
SILO Pharma Q1 EPS $(0.12) Up From $(0.23) YoY, Sales $18.026K, Same YoY
Benzinga · 05/14 20:20
Silo Pharma Q1 FY26 net loss widens 59.7% to $1.65 million
PUBT · 05/14 10:05
More
Webull provides a variety of real-time SILO stock news. You can receive the latest news about Silo Pharma Inc through multiple platforms. This information may help you make smarter investment decisions.
About SILO
Silo Pharma, Inc. is a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company. The Company’s therapeutic focus is on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. The Company’s portfolio includes programs, such as for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer’s disease and multiple sclerosis. Its lead product candidate, SPC-15, is designed as a novel serotonin 4 (5-HT4) receptor agonist that utilizes biomarkers for treatment of stress-induced psychiatric disorders such as PTSD and anxiety disorders. SPC-14 targets glutamate receptor NDMAR and serotonin 5-HT4 to address cognitive and neuropsychiatric symptoms in Alzheimer’s disease. SPU-16 is a candidate targeting central nervous system (CNS) disorders, with an initial indication for multiple sclerosis.